Clinical Trials

DDL110

• DDL110 is a new chemical entity (NCE).
• It increases the sAPPα to Aβ ratio and is multifunctional, interacting with two brain cell receptor pathways.
• It is very safe and enters the brain (passes the blood-brain barrier).
• Improved AD-like deficits in a mouse model of AD to a greater degree than currently approved drugs.
• It is currently moving towards clinical trials for treatement of MCI and AD in the US.

We already have one compound moving towards clinical trials as a result of using a straightforward approach to identify novel AD therapeutics based on their ability to increase sAPPα and the sAPPα/Aβ ratio. Through our screening and medicinal chemistry, we identified "DDL110" as an agent that increased those parameters. We compared DDL110 to two currently approved AD therapeutic drugs (memantine and donepezil) and saw greater improvements in memory in a mouse model of AD with DDL110. DDL110 is "multifunctional", that is, it interacts with at least two different receptors involved in cognitive function as well as APP itself.